Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma.

Abstract

Glioblastoma is the most common form of primary brain cancer. Its treatment involves surgery, radiotherapy, and chemotherapy with temozolomide (tmz), which is an oral alkylating agent. To the best of our knowledge, few dermatologic side effects of tmz have been described. We report two cases of cutaneous drug eruption caused by tmz during and after radiochemotherapy treatment. In the first case, all tests were negative, but the clinical history and the time of onset supported an allergy to tmz. In the second case, an allergy to tmz was proved by a positive lymphocyte activation test. In this context, our study is one of a very few trying to determine dermatologic side effects by applicable tests used in routine practice.

• Authors: E Deluche, S Leobon, F Touraine, P Clavère
• Journal: Current oncology (Toronto, Ont.) (Curr Oncol) Vol. 21 Issue 6 Pg. e779-81 (Dec 2014) ISSN: 1198-0052 [Print] Switzerland
• PMID: 25489267 (Publication Type: Journal Article)